A Phase I Dose Escalation Trial of WT1-Specific T Cells for Residual or Relapsed Leukemia After Allogeneic Hematopoietic Progenitor Cell Transplantation
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 28 Feb 2019
At a glance
- Drugs WT1 protein-specific T-cell therapy Atara/MSKCC (Primary)
- Indications Leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions
- 25 Feb 2019 Planned End Date changed from 1 Feb 2019 to 1 Feb 2020.
- 25 Feb 2019 Planned primary completion date changed from 1 Feb 2019 to 1 Feb 2020.
- 31 Aug 2018 Biomarkers information updated